Red Noise in Steady-State Multiphase Flow in Porous Media

Understanding the interaction between competing fluids in the pore space of rocks is key for predicting subsurface flow and trapping, such as with CO2 in a saline aquifer. These processes occur over a large span of timescales (from seconds to thousands of years), and length scales (from microns to kilometers). Understanding the link between these temporal and spatial scales will enable us to interpolate between observations made at different resolutions. In this work we explore the temporal scales present during macroscopically steady-state multiphase flow in a porous carbonate rock using differential pressure measurements acquired over a period of 60 min. Nitrogen and brine were injected simultaneously into a sample 5 mm in diameter and 21 mm in length. We observe a cascade of timescales in the pressure differential that is, a continuous range of frequencies, with lower frequencies having greater amplitudes. We demonstrate a scaling of the spectral density with frequency of S ∼ 1/f2, or red noise, to describe the dynamics. This scaling is independent of the flow rate of the fluids or the fraction of the flow taken by water. This red, or Brownian, noise indicates a stochastic process where pressure fluctuations are seen throughout the pore space, resulting in intermittent filling of pores over a wide range of time-scales, from seconds to minutes in these experiments. The presence of red noise suggests self-organized critically, with no characteristic time or length scale.</p

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to &lt; 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of &amp; GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P &lt; 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo